Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysis
IDH mutation status significantly affects time to first but not second recurrence. This study offers insight into recurrence patterns and highlights disparities in disease progression.
Authors
- Sabrina Begley
- Anne Lally
- Yonah Ziemba (ORCID: https://orcid.org/0000-0002-9308-2695)
- Joshua Reynolds (ORCID: https://orcid.org/0000-0001-6680-5993)
- Michael Schulder (ORCID: https://orcid.org/0000-0003-1802-8223)
- Isabella L. Pecorari (ORCID: https://orcid.org/0000-0002-1474-2553)
- Eric Zhu
- Elizabeth Juarez Diaz (ORCID: https://orcid.org/0000-0002-5804-3287)
- Alexander J. Ledet (ORCID: https://orcid.org/0000-0001-8420-2934)
- Karan Joseph (ORCID: https://orcid.org/0000-0001-9583-9957)
- Tanner M. Johanns (ORCID: https://orcid.org/0000-0003-1094-1528)
- Sayak R. Ghosh (ORCID: https://orcid.org/0009-0001-0247-0845)
- Vijay Agarwal
- Kyle McGeehan
Institutions
- Albert Einstein College of Medicine (US)
- Washington University in St. Louis (US)
- Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
Publication Details
- Journal
- Journal of Neuro-Oncology
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1007/s11060-025-05049-2
- Citations
- 2
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.25